- Home
- CAN vs RZLT Comparison
CAN vs RZLT Comparison
Compare CAN & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- RZLT
- Stock Information
- Founded
- CAN 2013
- RZLT 2010
- Country
- CAN Singapore
- RZLT United States
- Employees
- CAN N/A
- RZLT 20
- Industry
- CAN Semiconductors
- RZLT Biotechnology: Pharmaceutical Preparations
- Sector
- CAN Technology
- RZLT Health Care
- Exchange
- CAN Nasdaq
- RZLT Nasdaq
- Market Cap
- CAN 330.5M
- RZLT 626.4M
- IPO Year
- CAN 2019
- RZLT N/A
- Fundamental
- Price
- CAN $0.78
- RZLT $7.19
- Analyst Decision
- CAN Strong Buy
- RZLT Strong Buy
- Analyst Count
- CAN 6
- RZLT 5
- Target Price
- CAN $2.50
- RZLT $12.50
- AVG Volume (30 Days)
- CAN 34.8M
- RZLT 680.6K
- Earning Date
- CAN 08-14-2025
- RZLT 09-18-2025
- Dividend Yield
- CAN N/A
- RZLT N/A
- EPS Growth
- CAN N/A
- RZLT N/A
- EPS
- CAN N/A
- RZLT N/A
- Revenue
- CAN $345,360,000.00
- RZLT N/A
- Revenue This Year
- CAN $115.67
- RZLT N/A
- Revenue Next Year
- CAN $63.75
- RZLT N/A
- P/E Ratio
- CAN N/A
- RZLT N/A
- Revenue Growth
- CAN 82.40
- RZLT N/A
- 52 Week Low
- CAN $0.53
- RZLT $2.22
- 52 Week High
- CAN $3.27
- RZLT $7.46
- Technical
- Relative Strength Index (RSI)
- CAN 55.55
- RZLT 79.48
- Support Level
- CAN $0.64
- RZLT $6.23
- Resistance Level
- CAN $0.77
- RZLT $7.46
- Average True Range (ATR)
- CAN 0.05
- RZLT 0.28
- MACD
- CAN 0.01
- RZLT 0.05
- Stochastic Oscillator
- CAN 78.14
- RZLT 87.30
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About RZLT Rezolute Inc. (NV)
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.